SEC Form 4 · accession 0001179110-19-003309
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Landsittel
Officer — Chief Financial Officer
Period of report
Mar 1, 2019
Accepted (ET)
Mar 5, 2019 · 5:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $86.60 | Mar 1, 2019 | A | 19,500 | A | — | Mar 1, 2029 | Common Stock | 19,500 | 19,500 | D |
| Restricted Stock UnitsF2,F3 | — | Mar 1, 2019 | A | 5,250 | A | — | — | Common Stock | 5,250 | 5,250 | D |
Explanation of responses
- F1This option vests with respect to 1/48th of the shares underlying the option on April 1, 2019 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- F2Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3The restricted stock units vest in four equal annual installments on March 1, 2020, 2021, 2022 and 2023.